Sulfinpyrazone/Hydantoins Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process your seizure medicine properly.
What might happen:
Your blood levels of seizure medicine may rise and cause an increase in the beneficial and toxic effects.
What you should do about this interaction:
If you experience loss of coordination, nausea, vomiting, weakness, dizziness, or fatigue, contact your doctor. It may be necessary to check your blood levels of seizure medicine. Your doctor may need to adjust the dose.Your healthcare professionals (e.g. doctor or pharmacist) may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
- 2.Glazko AJ. Antiepileptic drugs: biotransformation, metabolism, and serum half-life. Epilepsia 1975 Jun;16(2):367-91.
- 3.Kurata D, Wilkinson GR. Erythrocyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther 1974 Aug;16(2):355-62.
- 4.Lunde PK, Rane A, Yaffe SJ, Lund L, Sjoqvist F. Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther 1970 Nov-Dec; 11(6):846-55.
- 5.Neuvonen PJ, Lehtovaara R, Bardy A, Elomaa E. Antipyretic analgesics in patients on antiepileptic drug therapy. Eur J Clin Pharmacol 1979 May 21; 15(4):263-8.
- 6.Pedersen AK, Jakobsen P, Kampmann JP, Hansen JM. Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone. Clin Pharmacokinet 1982 Jan-Feb;7(1):42-56.
- 7.Lucas BG. "Dilantin" overdosage. Med J Aust 1968 Oct 12;2(15):639-40.
- 8.Soda DM, Levy G. Inhibition of drug metabolism by hydroxylated metabolites: cross- inhibition and specificity. J Pharm Sci 1975 Dec; 64(12):1928-31.
- 9.Dilantin (phenytoin sodium) US prescribing information. Pfizer, Inc. March, 2022.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.